Efficacy of tetrandrine on lowering intraocular pressure in animal model with ocular hypertension

Journal of Glaucoma

Volumn 20, Issue 3, 2011, Pages 183-188

  Huang, Ping ^a   Xu, Yongsheng ^a   Wei, Ruoxin ^a   Li, Haiping ^a   Tang, Yong ^a,c   Liu, Jing ^a   Zhang, Samuel Shao Min ^b   Zhang, Chun ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c TIANJIN EYE HOSPITAL   (China)

Author keywords

animal model with ocular hypertension; eye drops; tetrandrine

Indexed keywords

OXYBUPROCAINE; PROXYMETACAINE; SODIUM CHLORIDE; TETRANDRINE; TIMOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIODE LASER; DRUG EFFICACY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SOLUTION AND SOLUBILITY; TONOMETER;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZYLISOQUINOLINES; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; RATS; RATS, SPRAGUE-DAWLEY; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 84855167212     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181d7882a     Document Type: Article

References (24)

1. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthalmol. 2003;48(suppl 1):S3-S7. (Pubitemid 41126689)
2. Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin Pharmacother. 2007;8:3237-3249.
3. Wang RF, Gagliuso DJ, Podos SM. Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys. J Glaucoma. 2008;17:73-78. (Pubitemid 351321482)
4. Abreu MM, Kim YY, Shin DH, et al. Topical verapamil and episcleral venous pressure. Ophthalmology. 1998;105:2251-2255. (Pubitemid 30191667)
5. Zornow MH, Prough DS. Neuroprotective properties of calcium-channel blockers. New Horiz. 1996;4:107-114. (Pubitemid 26109255)
6. Wang G, Lemos JR, Iadecola C. Herbal alkaloid tetrandrine: from an ion channel blocker to inhibitor of tumor proliferation. Trends Pharmacol Sci. 2004;25:120-123. (Pubitemid 38264500)
7. Yao WX, Jiang MX. Effects of tetrandrine on cardiovascular electrophysiologic properties. Acta Pharmacol Sin. 2002;23:1069-1074.
8. Wang G, Lemos JR. Tetrandrine: a new ligand to block voltage-dependent Ca2+ and Ca(+)-activated K+ channels. Life Sci. 1995;56:295-306. (Pubitemid 124014538)
9. Kwan CY, Achike F. Tetrandrine and related bisbenzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action. Acta Pharmacol Sin. 2002;23:1057-1068. (Pubitemid 35470328)
10. King VF, Garcia ML, Himmel D, et al. Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin. J Bio Chem. 1988;263:2238-2244. (Pubitemid 18060279)
11. 2+ channels. Eur J Pharmacol. 2003;466:63-71.
12. Ransom CB, Liu X, Sontheimer H. BK channels in human glioma cells have enhanced calcium sensitivity. Glia. 2002;38:281-291.
13. Liu SX, Chiou GC. Effects of Chinese herbal products on mammalian retinal functions. J Ocul Pharmacol Ther. 1996;12:377-386. (Pubitemid 26335457)
14. Hu S, Merayo-Lloves J, Zhao T, et al. Potent inhibitory effect of tetrandrine on experimental allergic conjunctivitis in mice. J Ocul Pharmacol Ther. 1997;13:435-444. (Pubitemid 28090235)
15. Levkovitch-Verbin H, Quigley HA, Martin KR, et al. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest Ophthalmol Vis Sci. 2002;43:402-410. (Pubitemid 34113222)
16. Moore CG, Milne ST, Morrison JC. Noninvasive measurement of rat intraocular pressure with the Tono-Pen. Invest Ophthalmol Vis Sci. 1993;34:363-369. (Pubitemid 23072870)
17. Moore CG, Epley D, Milne ST, et al. Long-term non-invasive measurement of intraocular pressure in the rat eye. Curr Eye Res. 1995;14:711-717.
18. Akaishi T, Odani-Kawabata N, Ishida N, et al. Ocular hypotensive effects of anti-glaucoma agents in mice. J Ocul Pharmacol Ther. 2009;25:401-408.
19. Chiu K, Chang R, So KF. Laser-induced chronic ocular hypertension model on SD rats. J Vis Exp. 2007;10:549.
20. Kitano A, Yamanaka O, Ikeda K, et al. Tetrandrine suppresses activation of human subconjunctival fibroblasts in vitro. Curr Eye Res. 2008;33:559-565. (Pubitemid 351948482)
21. Liu QY, Li B, Gang JM, et al. Tetrandrine, a Ca++ antagonist: effects and mechanisms of action in vascular smooth muscle cells. J Pharmacol Exp Ther. 1995;273:32-39.
22. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res. 2000;19:271-295. (Pubitemid 30122724)
23. Ho LJ, Lai JH. Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. Curr Drug Metab. 2004;5:181-192.
24. Qin LX, Guo JW. Effects of tetrandrine on ultrastructure of cultured conjunctival fibroblasts and toxicity to intraocular tissues in rabbit. Recent Adv Ophthalmol. 2004;24:273-275.